Altasciences has contributed to the recent FDA approval of Vibegron, a beta-3 adrenergic receptor (β3) agonist for the treatment of overactive bladder, conducting multiple early phase clinical trialsfor Urovant Sciences.   Altasciences provided clinical support for two drug-drug interaction studies and a bioavailability trial, conducted in 2018 and 2019, in healthy subjects. These trials were supported by Altasciences’ data services team, who performed the full data management and reporting fo...